Nascent Biotech Inc.
NBIODelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001622057
Nascent Biotech Inc. was delisted in 2024; its insiders filed their last Form 4 on Jul 2, 2024; no institution reported holding it in 13F filings for Q3 2024; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Nascent Biotech Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Nascent Biotech Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Karas Douglas John | Director | 1,821,552 | Jul 2, 2024 | 0 |
| Holden Lowell Thomas | CFO | 10,005,477 | Jul 2, 2024 | 0 |
| Carrick Sean | President & CEO | 23,126,007 | Jul 2, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2023 (view filing)3:28 PM ET | Jun 7 | 2 days | Holden Lowell ThomasCFO | PPurchase | +130.0K | $0.04 | +$5.20K | +1.6%8.41M after | |
| Feb 2, 2023 (view filing)3:04 PM ET | Jan 27 | 6 daysLate | Holden Lowell ThomasCFO | PPurchase | +20.0K | $0.14 | +$2.80K | +0.2%8.42M after | Duplicate filing |
| Feb 2, 2023 (view filing)12:47 PM ET | Jan 27 | 6 daysLate | Holden Lowell ThomasCFO | PPurchase | +20.0K | $0.14 | +$2.80K | +0.2%8.42M after | |
| Jul 25, 2022 (view filing)11:24 AM ET | Jul 21 | 4 days | Holden Lowell ThomasCFO | SSale | −5.00K | $0.26 | −$1.30K | −0.1%8.11M after |